NEW YORK (GenomeWeb News) – Roche today said that med fusion, a Lewisville, Texas-based clinical lab and clinical trials services firm, has been named a Roche Molecular Center of Excellence for the next five years.

As part of the designation, med fusion will offer a range of Roche's molecular technologies including the cobas 4800 V600 Mutation Test, a companion diagnostic approved by the US Food and Drug Administration last year for identifying patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.